TapImmune, Inc. (TPIM/TPIM.OB) Wrap Up:

TapImmune, Inc., a development stage company, engages in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. The company focuses on conducting studies using its transporters of antigen processing (TAP) gene technology in combination with an in-licensed adeno virus. Its products include TAP cancer vaccine used for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company also develops vaccines for infectious diseases using its TAP gene technology and an in-licensed modified vaccinia ankora virus. It has strategic ...